by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia
Abstract INTRODUCTION Electro-acupuncture (EA) has demonstrated potential in improving mild-to-moderate dementia in clinics, but the underlying scientific target remains unclear. METHODS EA was administered to APP/PS1 Alzheimer’s disease (AD) mice, with...
by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia
Abstract INTRODUCTION Small molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides. METHODS We describe MEDI1814, a fully human high-affinity monoclonal antibody selective for Aβ42, the pathogenic self-aggregating species of Aβ. RESULTS...
by Clinical Neuropsychologist | Wednesday, September 25, 2024 | Dementia
Abstract INTRODUCTION The Alzheimer’s Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer’s disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat’s side...
by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia
Abstract The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for...
by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia
Abstract INTRODUCTION We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs). METHODS We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the...